NO20040314L - Nye forbindelser - Google Patents

Nye forbindelser

Info

Publication number
NO20040314L
NO20040314L NO20040314A NO20040314A NO20040314L NO 20040314 L NO20040314 L NO 20040314L NO 20040314 A NO20040314 A NO 20040314A NO 20040314 A NO20040314 A NO 20040314A NO 20040314 L NO20040314 L NO 20040314L
Authority
NO
Norway
Prior art keywords
sub
new connections
therapy
processes
formula
Prior art date
Application number
NO20040314A
Other languages
English (en)
Norwegian (no)
Inventor
Craig Johnstone
David Griffiths
Original Assignee
Astrazeneca Ab Global Ip
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab Global Ip filed Critical Astrazeneca Ab Global Ip
Publication of NO20040314L publication Critical patent/NO20040314L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cephalosporin Compounds (AREA)
  • Use Of Switch Circuits For Exchanges And Methods Of Control Of Multiplex Exchanges (AREA)
NO20040314A 2001-07-25 2004-01-23 Nye forbindelser NO20040314L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0102617A SE0102617D0 (sv) 2001-07-25 2001-07-25 Novel compounds
PCT/SE2002/001402 WO2003010163A1 (fr) 2001-07-25 2002-07-19 Nouveaux composes

Publications (1)

Publication Number Publication Date
NO20040314L true NO20040314L (no) 2004-03-25

Family

ID=20284945

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20040314A NO20040314L (no) 2001-07-25 2004-01-23 Nye forbindelser

Country Status (17)

Country Link
US (1) US7098240B2 (fr)
EP (1) EP1421079B1 (fr)
JP (2) JP2004536869A (fr)
KR (1) KR20040018521A (fr)
CN (1) CN1538968A (fr)
AT (1) ATE353327T1 (fr)
BR (1) BR0211472A (fr)
CA (1) CA2454702A1 (fr)
DE (1) DE60218048T2 (fr)
ES (1) ES2280559T3 (fr)
IL (1) IL160023A0 (fr)
MX (1) MXPA04000755A (fr)
NO (1) NO20040314L (fr)
NZ (1) NZ530751A (fr)
SE (1) SE0102617D0 (fr)
WO (1) WO2003010163A1 (fr)
ZA (1) ZA200400494B (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0003154D0 (en) * 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
US6881741B2 (en) * 2001-06-11 2005-04-19 Virochem Pharma Inc. Compounds and methods for the treatment or prevention of Flavivirus infections
SE0102616D0 (sv) * 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
EP1448545B1 (fr) * 2001-10-04 2008-11-19 Smithkline Beecham Corporation Inhibiteurs du facteur de transcription nf-kb
US7375131B2 (en) * 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
KR101058696B1 (ko) * 2002-12-10 2011-08-22 바이로켐 파마 인코포레이티드 후라비바이러스 감염의 치료 또는 예방을 위한 화합물과방법
SE0300092D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
SE0300091D0 (sv) 2003-01-15 2003-01-15 Astrazeneca Ab Novel compounds
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
US20050113566A1 (en) * 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
MXPA05011503A (es) * 2003-04-25 2006-05-31 Johnson & Johnson Inhibidores de la c-fms cinasa.
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
EP1493739A1 (fr) * 2003-07-03 2005-01-05 Warner-Lambert Company LLC Dérivés thiophényliques d'aminoacides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
US20050085531A1 (en) * 2003-10-03 2005-04-21 Hodge Carl N. Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
ATE501138T1 (de) * 2004-01-05 2011-03-15 Astrazeneca Ab Thiophenderivate als chk-1-inhibitoren
AR050253A1 (es) 2004-06-24 2006-10-11 Smithkline Beecham Corp Compuesto derivado de indazol carboxamida, composicion que lo comprende y su uso para la preparacion de un medicamento
PE20060748A1 (es) 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
WO2006119646A1 (fr) * 2005-05-13 2006-11-16 Virochem Pharma Inc. Composés et méthodes pour le traitement prophylactique ou thérapeutique d'infections par un flavivirus
US8063071B2 (en) 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
AR055343A1 (es) 2005-06-30 2007-08-22 Smithkline Beecham Corp Derivados de indolcarboxamida inhibidores de quinasas ikk2
JP5290186B2 (ja) * 2006-11-15 2013-09-18 ヴァイロケム ファーマ インコーポレイテッド フラビウイルス感染症の治療または予防用のチオフェン類似体
JP5070067B2 (ja) * 2007-01-15 2012-11-07 参天製薬株式会社 ＩκＢキナーゼβ阻害活性を有する新規インドール誘導体
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
EP2278999B1 (fr) 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Préparations auriculaires de traitement de maladies et états otiques
CN102089281A (zh) * 2008-07-14 2011-06-08 参天制药株式会社 具有氨基甲酰基、脲基及取代氧基的新型吲哚衍生物
EP2319831A4 (fr) * 2008-08-25 2012-10-24 Santen Pharmaceutical Co Ltd Nouveau dérivé de pyrrole ayant, en tant que substituants, un groupe uréide, un groupe aminocarbonyle et un groupe bicyclique qui peut avoir un substituant
WO2010102968A1 (fr) 2009-03-10 2010-09-16 Glaxo Group Limited Dérivés d'indole comme inhibiteurs de ikk2
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (fr) 2009-11-17 2011-05-26 Astrazeneca Ab Combinaisons qui comprennent un modulateur du récepteur glucocorticoïde, destinées au traitement de maladies respiratoires
GB201016912D0 (en) 2010-10-07 2010-11-24 Astrazeneca Ab Novel combination
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
EP2520292A1 (fr) 2011-05-06 2012-11-07 Helmholtz-Zentrum für Infektionsforschung GmbH Utilisation de spirangiens pour le traitement ou la prévention des troubles liés à IL-8 ou IL-6
AU2017290256A1 (en) 2016-06-29 2019-01-17 Otonomy, Inc. Triglyceride otic formulations and uses thereof
CN107739370B (zh) * 2017-10-26 2021-03-30 中国药科大学 吡咯酮类brd4蛋白抑制剂的制备方法以及用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1468012A (en) * 1973-08-09 1977-03-23 Beecham Group Ltd 2-amino-3-carboxy-thiophene derivatives
DE3529247A1 (de) 1985-05-17 1986-11-20 Bayer Ag, 5090 Leverkusen Verwendung von thienylharnstoffen und -isoharnstoffen als leistungsfoerdernde mittel bei tieren, neue thienylharnstoffe und -isoharnstoffe und ihre herstellung
EP0912548A1 (fr) 1996-07-11 1999-05-06 Pfizer Inc. Composes de pyridylpyrrole utiles comme antagonistes de l'interleukine et du facteur tnf
PT853083E (pt) * 1997-01-06 2001-12-28 Pfizer Composto de piridilfurano e piridiltiofeno e sua utilizacao farmaceutica
US6809088B2 (en) * 1997-03-24 2004-10-26 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
US6037340A (en) 1997-05-28 2000-03-14 Cadus Pharmaceutical Corporation Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
DE19744026A1 (de) 1997-10-06 1999-04-08 Hoechst Marion Roussel De Gmbh Pyrazol-Derivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
WO1999046244A1 (fr) 1998-03-12 1999-09-16 Novo Nordisk A/S Modulateurs de proteine tyrosine phosphatases (ptpases)
HN2000000051A (es) * 1999-05-19 2001-02-02 Pfizer Prod Inc Derivados heterociclicos utiles como agentes anticancerosos
CN100355751C (zh) * 2000-03-29 2007-12-19 西克拉塞尔有限公司 2－取代的4－杂芳基－嘧啶、其组合物及其用途
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
EP1324759A4 (fr) 2000-10-12 2004-05-12 Smithkline Beecham Corp Inhibiteurs du nf-g(k)b

Also Published As

Publication number Publication date
BR0211472A (pt) 2004-11-09
CN1538968A (zh) 2004-10-20
ZA200400494B (en) 2005-04-22
IL160023A0 (en) 2004-06-20
ATE353327T1 (de) 2007-02-15
SE0102617D0 (sv) 2001-07-25
WO2003010163A1 (fr) 2003-02-06
MXPA04000755A (es) 2004-04-20
JP2010111683A (ja) 2010-05-20
NZ530751A (en) 2005-09-30
CA2454702A1 (fr) 2003-02-06
ES2280559T3 (es) 2007-09-16
US7098240B2 (en) 2006-08-29
US20040235821A1 (en) 2004-11-25
JP2004536869A (ja) 2004-12-09
EP1421079A1 (fr) 2004-05-26
EP1421079B1 (fr) 2007-02-07
DE60218048D1 (de) 2007-03-22
DE60218048T2 (de) 2007-08-09
KR20040018521A (ko) 2004-03-03

Similar Documents

Publication Publication Date Title
NO20040314L (no) Nye forbindelser
DK1421074T3 (da) Nye forbindelser
GB0003154D0 (en) Novel compounds
NO20023934D0 (no) Nye forbindelser
SE0102439D0 (sv) New compounds
SE0302116D0 (sv) Novel compounds
NO20026064D0 (no) Nye forbindelser
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
MY129751A (en) New dihydropteridinones, processes for preparing them and their use as medicaments.
SE0103836D0 (sv) Novel compounds
HUP0401783A2 (hu) 3,4-Diszubsztituált ciklobutén-1,2-dionok mint CXC-kemokin receptor ligandumok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
CY1107817T1 (el) Καρβοξαμιδια θειοφαινιου ως αναστολεις του ενζυμου ικκ-2
HRP20041137B1 (hr) Indolni, azaindolni i srodni heterocikliäśni 4-alkenil piperidinski amidi
SE0100569D0 (sv) New compounds
NO20090327L (no) Nye forbindelser 384
SE0300092D0 (sv) Novel compounds
SE0101322D0 (sv) Novel compounds
NO20034215L (no) Nye amider, fremstilling og terapeutisk anvendelse av modulatorer av CCR-reseptoraktivitet
DE602004019914D1 (de) Colchicosidanaloge
ATE298564T1 (de) Arzneimittelformulierung enthaltend einen ltb4 antagonisten und einen netzmittel